Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5

被引：11

作者：

Gong, Xudong ^{[1
]}

Wang, Guan ^{[2
]}

Ren, Jing ^{[2
]}

Liu, Zheng ^{[3
]}

Wang, Zhen ^{[2
]}

Chen, Tiantian ^{[2
]}

Yang, Xiaojun ^{[3
]}

Jiang, Xiangrui ^{[2
]}

Shen, Jingshan ^{[2
]}

Jiang, Hualiang ^{[2
]}

Aisa, Haji Akber ^{[1
]}

Xu, Yechun ^{[2
]}

Li, Jianfeng ^{[2
]}

机构：

[1] Chinese Acad Sci, Xinjiang Tech Inst Phys & Chem, Key Lab Xinjiang Indigenous Med Plants Resource U, Urumiqi 830011, Peoples R China

[2] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China

[3] Vitargeta Therapeut Inc, Plainsboro, NJ 08536 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 17期

基金：

中国国家自然科学基金; 国家高技术研究发展计划(863计划);

关键词：

PDE5; inhibitors; 5-Bromopyrimidin-4(3H)-ones; DRUG DEVELOPMENT; PHOSPHODIESTERASE-5; DESIGN;

D O I：

10.1016/j.bmcl.2013.06.062

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The substituents both at the 6-position of the 5-bromopyrimidinone ring and at the 5'-position of the phenyl ring of 5-bromopyrimidin-4(3H)-ones were explored. 5-Bromo-6-isopropyl-2-(2-propoxyphenyl)pyrimidin-4(3H)-one was identified as a new scaffold for potent PDE5 inhibitors. The crystal structures of PDE5/2e and PDE5/10a complexes provided a structural basis for the inhibition of 5-bromopyrimidinones to PDE5. In addition, it was also found that there is a great tolerance for the substitution at the 5'-position of the phenyl ring of 5-bormopyrimidinones and the resulted compound 13a has the highest inhibition activity to PDE5 (IC50, 1.7 nM). (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：4944 / 4947

页数：4

共 17 条

[11] Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules [J].

Sung, BJ ;

Hwang, KY ;

Jeon, YH ;

Lee, JI ;

Heo, YS ;

Kim, JH ;

Moon, J ;

Yoon, JM ;

Hyun, YL ;

Kim, E ;

Eum, SJ ;

Park, SY ;

Lee, JO ;

Lee, TG ;

Ro, S ;

Cho, JM .

NATURE, 2003, 425 (6953) :98-102

[12]

Tian G., 2007, [No title captured], Patent No. [EP1961753, 1961753]

[13]

Vassilev GN, 2002, OXID COMMUN, V25, P608

[14] Design, Synthesis, and Pharmacological Evaluation of Monocyclic Pyrimidinones as Novel Inhibitors of PDE5 [J].

Wang, Guan ;

Liu, Zheng ;

Chen, Tiantian ;

Wang, Zhen ;

Yang, Huaiyu ;

Zheng, Mingyue ;

Ren, Jing ;

Tian, Guanghui ;

Yang, Xiaojun ;

Li, Li ;

Li, Jianfeng ;

Suo, Jin ;

Zhang, Rongxia ;

Jiang, Xiangrui ;

Terrett, Nicholas Kenneth ;

Shen, Jingshan ;

Xu, Yechun ;

Jiang, Hualiang .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (23) :10540-10550

[15] Multiple conformations of phosphodiesterase-5 - Implications for enzyme function and drug development [J].

Wang, Huanchen ;

Liu, Yudong ;

Huai, Qing ;

Cai, Jiwen ;

Zoraghi, Roya ;

Francis, Sharron H. ;

Corbin, Jackie D. ;

Robinson, Howard ;

Xin, Zhongcheng ;

Lin, Guiting ;

Ke, Hengming .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (30) :21469-21479

[16] Utilization of Halogen Bond in Lead Optimization: A Case Study of Rational Design of Potent Phosphodiesterase Type 5 (PDE5) Inhibitors [J].

Xu, Zhijian ;

Liu, Zheng ;

Chen, Tong ;

Chen, TianTian ;

Wang, Zhen ;

Tian, Guanghui ;

Shi, Jing ;

Wang, Xuelan ;

Lu, Yunxiang ;

Yan, Xiuhua ;

Wang, Guan ;

Jiang, Hualiang ;

Chen, Kaixian ;

Wang, Shudong ;

Xu, Yechun ;

Shen, Jingshan ;

Zhu, Weiliang .

JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (15) :5607-5611

[17] Use of fluorous silica gel to separate fluorous thiol quenching derivatives in solution-phase parallel synthesis [J].

Zhang, W ;

Curran, DP ;

Chen, CHT .

TETRAHEDRON, 2002, 58 (20) :3871-3875

← 1 2 →